Lv11
30 积分 2024-01-25 加入
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
2小时前
已完结
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
5小时前
已完结
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
5天前
已完结
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials
5天前
已完结
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
5天前
已完结
Hashash JG, Limdi JK, Shapiro JM, Shah SA. Medical management of inflammatory bowel diseases
9天前
已关闭
The global burden of IBD: from 2015 to 2025
10天前
已完结
Phase 2, Randomized, Double-Blind, Placebo-controlled study of CRD-740, a PDE9 inhibitor, in chronic heart failure
30天前
已完结
Primary Glomerulonephritis in Mainland China: An Overview
1个月前
已完结
皖公网安备34019202002308
